Results of a clinical trial of the safety and efficacy profile of the trivalent inactivated polymer-subunit influenza vaccine Grippol® plus for infants aged 6 months to 3 years


Romanenko V.V., Ankudinova A.V., Averyanov O.Yu., Chebykina T.V., Spesivtseva L.Yu.

Center for Hygiene and Epidemiology in the Sverdlovsk Region, Yekaterinburg; Children’s City Clinical Hospital Eleven, Yekaterinburg
The paper presents the results of a clinical trial of the safety and efficacy of the vaccine Grippol® plus twice administered in doses of 0.25 ml (n=70) and 0.5 ml (n=70) at a 21-day interval in children aged 6 to 35 months. This is a randomized, double-blind controlled, parallel-group comparative study. The vaccine Grippol® plus twice administered in doses of 0.25 and 0.5 ml in children aged 6 to 35 months has been ascertained to have a weak reactogenicity and a pronounced immunological activity.

About the Autors


Romanenko Viktor Vasilyevich, MD; Deputy Head Physician, Center for Hygiene and Epidemiology in the Sverdlovsk Region
Address: 3, Otdelnyi Per., Yekaterinburg 620078
Telephone: (343)270-15-63
E-mail: Romanenko_VV@66.rospotrebnadzor.ru


Similar Articles


Бионика Медиа